The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder

Henry M. Rosevear, Andrew J. Lightfoot, Michael A. O'Donnell, Thomas S. Griffith

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Abstract

Intravesical Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy is a highly effective treatment for carcinoma in situ of the bladder, as well as high-risk nonmuscle invasive urothelial carcinoma of the bladder. Despite over 30 years of clinical experience with BCG, the therapy's mechanism has remained enigmatic. Observations regarding the role of neutrophils in BCG immunotherapy have led to exciting discoveries regarding the potential role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in creating the therapeutic benefit of BCG immunotherapy. In this paper, we will review the scope of the disease, highlight our understanding of the role for BCG in urothelial carcinoma of the bladder, explain the recent discoveries regarding the role of neutrophils and TRAIL in therapy, and theorize on potential future areas of research.

Original languageEnglish (US)
Pages (from-to)345-353
Number of pages9
JournalCancer and Metastasis Reviews
Volume28
Issue number3-4
DOIs
StatePublished - Dec 7 2009

Keywords

  • BCG
  • Bladder cancer
  • Neutrophil
  • TRAIL
  • Urothelial carcinoma

Fingerprint Dive into the research topics of 'The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder'. Together they form a unique fingerprint.

Cite this